0001193125-26-219428
SEC filingRevenue accelerated 83% to $3.9M from higher units sold and average selling prices, driving gross profit up 124% to $2.0M at 50.7% margin, while operating losses narrowed 21.5% to -$8.6M through cost discipline amid ongoing commercialization investments.
Cash from operating activities used -$9.0 million, an improvement from -$9.2 million prior year, with capital expenditures dropping to $242 thousand from $472 thousand, resulting in -$9.2 million free cash flow. This reflects moderated cash burn as investments support product launches like the next-generation Swoop system powered by Optive AI software, enabling expansion into clinics and international markets.
Management notes future capital needs will depend on development costs, commercialization strategy, regulatory progress, supply constraints, manufacturing scale, and global expansion. While technical innovations may elevate R&D temporarily, they are expected to enhance long-term profitability. Investment policy prioritizes liquidity and capital preservation to navigate these dynamics.